Dataset Information

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.

ABSTRACT: BACKGROUND:Parkinson's disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression. METHODS:CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n?=?44; multiple system atrophy (MSA), n?=?14; vascular parkinsonism (VaP), n?=?9; and PD with VaP, n?=?7) and controls (n?=?25) were analyzed. RESULTS:Concentrations of CCL28 were elevated in PD compared to controls (p?=?0.0001). Five other biomarkers differentiated both MSA and PD from controls (p??0.650; p?

SUBMITTER: Santaella A

PROVIDER: S-EPMC6967088 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.

Santaella Anna A Kuiperij H Bea HB van Rumund Anouke A Esselink Rianne A J RAJ van Gool Alain J AJ Bloem Bastiaan R BR Verbeek Marcel M MM

BMC neurology 20200117 1

<h4>Background</h4>Parkinson's disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.<h4>Methods</h4>CSF from ...[more]

PMID: 31952511

Similar Datasets

Project description:Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive heterogeneous neurodegenerative diseases that share clinical characteristic of parkinsonism as a common feature, but are considered distinct clinicopathological disorders. Based on the predominant protein aggregates observed within the brain, these disorders are categorized as, (1) ?-synucleinopathies, which include PD and other Lewy body spectrum disorders as well as multiple system atrophy, and (2) tauopathies, which comprise progressive supranuclear palsy and corticobasal degeneration. Although, great strides have been made in neurodegenerative disease research since the first medical description of PD in 1817 by James Parkinson, these disorders remain a major diagnostic and treatment challenge. A valid diagnosis at early disease stages is of paramount importance, as it can help accommodate differential prognostic and disease management approaches, enable the elucidation of reliable clinicopathological relationships ideally at prodromal stages, as well as facilitate the evaluation of novel therapeutics in clinical trials. However, the pursuit for early diagnosis in PD and atypical Parkinsonian syndromes is hindered by substantial clinical and pathological heterogeneity, which can influence disease presentation and progression. Therefore, reliable neuroimaging biomarkers are required in order to enhance diagnostic certainty and ensure more informed diagnostic decisions. In this article, an updated presentation of well-established and emerging neuroimaging biomarkers are reviewed from the following modalities: (1) structural magnetic resonance imaging (MRI), (2) diffusion-weighted and diffusion tensor MRI, (3) resting-state and task-based functional MRI, (4) proton magnetic resonance spectroscopy, (5) transcranial B-mode sonography for measuring substantia nigra and lentiform nucleus echogenicity, (6) single photon emission computed tomography for assessing the dopaminergic system and cerebral perfusion, and (7) positron emission tomography for quantifying nigrostriatal functions, glucose metabolism, amyloid, tau and ?-synuclein molecular imaging, as well as neuroinflammation. Multiple biomarkers obtained from different neuroimaging modalities can provide distinct yet corroborative information on the underlying neurodegenerative processes. This integrative "multimodal approach" may prove superior to single modality-based methods. Indeed, owing to the international, multi-centered, collaborative research initiatives as well as refinements in neuroimaging technology that are currently underway, the upcoming decades will mark a pivotal and exciting era of further advancements in this field of neuroscience.

Dataset Information

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.

Publications

Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets